{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T07:08:06Z","timestamp":1774854486452,"version":"3.50.1"},"reference-count":131,"publisher":"Bentham Science Publishers Ltd.","issue":"19","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2019,12,9]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>One-third of the world\u2019s population harbours the latent tuberculosis infection (LTBI) with a\nlifetime risk of reactivation. Although, the treatment of LTBI relies significantly on the first-line\ntherapy, identification of novel drug targets and therapies are the emerging focus for researchers across\nthe globe. The current review provides an insight into the infection, diagnostic methods and\nepigrammatic explanations of potential molecular targets of dormant phase bacilli. This study also\nincludes current preclinical and clinical aspects of tubercular infections and new approaches in antitubercular\ndrug discovery.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557519666190625165512","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T05:55:10Z","timestamp":1561528510000},"page":"1627-1642","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Latent Tuberculosis Infection (LTBI) and Its Potential Targets: An Investigation into Dormant Phase Pathogens"],"prefix":"10.2174","volume":"19","author":[{"given":"Gopichand","family":"Gutti","sequence":"first","affiliation":[{"name":"Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (B.H.U.) Varanasi-221005 (U.P.), India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karan","family":"Arya","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (B.H.U.) Varanasi-221005 (U.P.), India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushil Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (B.H.U.) Varanasi-221005 (U.P.), India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/187153008783928398","volume":"8","author":"Lin M.Y.","year":"2008","unstructured":"Lin M.Y.; Ottenhoff T.H.; Host-pathogen interactions in latent Mycobacterium tuberculosis infection: Identification of new targets for tuberculosis intervention. Endocr Metab Immune Disord Drug Targets 2008,8(1),15-29","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/0300985811429313","volume":"49","author":"Sakamoto K.","year":"2012","unstructured":"Sakamoto K.; The pathology of Mycobacterium tuberculosis infection. Veterin Pathol 2012,49(3),423-439","journal-title":"Veterin Pathol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/187152807780077282","volume":"6","author":"Cardona P.J.","year":"2007","unstructured":"Cardona P.J.; New insights on the nature of latent tuberculosis infection and its treatment. Inflamm Allergy Drug Targets 2007,6(1),27-39","journal-title":"Inflamm Allergy Drug Targets"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4049\/jimmunol.0903856","volume":"185","author":"Lin P.L.","year":"2010","unstructured":"Lin P.L.; Flynn J.L.; Understanding latent tuberculosis: A moving target. J Immunol 2010,185(1),15-22","journal-title":"J Immunol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/rccm.2109089","volume":"166","author":"Weis S.E.","year":"2002","unstructured":"Weis S.E.; Pogoda J.M.; Yang Z.; Cave M.D.; Wallace C.; Kelley M.; Barnes P.F.; Transmission dynamics of tuberculosis in Tarrant county, Texas. Am J Respir Crit Care Med 2002,166(1),36-42","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jama.1997.03550140051039","volume":"278","author":"Barnes P.F.","year":"1997","unstructured":"Barnes P.F.; Yang Z.; Preston-Martin S.; Pogoda J.M.; Jones B.E.; Otaya M.; Eisenach K.D.; Knowles L.; Harvey S.; Cave M.D.; Patterns of tuberculosis transmission in Central Los Angeles. JAMA 1997,278(14),1159-1163","journal-title":"JAMA"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1056\/NEJM199406163302402","volume":"330","author":"Small P.M.","year":"1994","unstructured":"Small P.M.; Hopewell P.C.; Singh S.P.; Paz A.; Parsonnet J.; Ruston D.C.; Schecter G.F.; Daley C.L.; Schoolnik G.K.; The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994,330(24),1703-1709","journal-title":"N Engl J Med"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"971","DOI":"10.7326\/0003-4819-130-12-199906150-00004","volume":"130","author":"Jasmer R.M.","year":"1999","unstructured":"Jasmer R.M.; Hahn J.A.; Small P.M.; Daley C.L.; Behr M.A.; Moss A.R.; Creasman J.M.; Schecter G.F.; Paz E.A.; Hopewell P.C.; A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med 1999,130(12),971-978","journal-title":"Ann Intern Med"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00586-012-2334-8","volume":"22","author":"Millet J-P.","year":"2013","unstructured":"Millet J-P.; Moreno A.; Fina L.; Del Ba\u00f1o L.; Orcau A.; De Olalla P.G.; Cayla J.A.; Factors that influence current tuberculosis epidemiology. Eur Spine J 2013,22(4),539-548","journal-title":"Eur Spine J"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJM199212103272401","volume":"327","author":"Selwyn P.A.","year":"1992","unstructured":"Selwyn P.A.; Alcabes P.; Hartel D.; Buono D.; Schoenbaum E.E.; Klein R.S.; Davenny K.; Friedland G.H.; Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992,327(24),1697-1703","journal-title":"N Engl J Med"},{"key":"ref=11","first-page":"1-214","year":"2016","unstructured":"Global Tuberculosis Report 2016. World Health Organization \n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/apps.who.int\/medicinedocs\/documents\/s23098en\/s23098en.pdf\">http:\/\/apps.who.int\/medicinedocs\/documents\/s23098en\/s23098en.pdf (Accessed June 07, 2017).2016,1-214","journal-title":"World Health Organization"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1586\/17476348.2.4.455","volume":"2","author":"Tomioka H.","year":"2008","unstructured":"Tomioka H.; Tatano Y.; Yasumoto K.; Shimizu T.; Recent advances in antituberculous drug development and novel drug targets. Expert Rev Respir Med 2008,2(4),455-471","journal-title":"Expert Rev Respir Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.2174\/1389557517666170220152651","volume":"18","author":"Sellamuthu S.","year":"2017","unstructured":"Sellamuthu S.; Bhat M.; Kumar A.; Singh S.; Phenothiazine: A better Scaffold against Tuberculosis. Mini Rev Med Chem 2017,18(17),1442-1451","journal-title":"Mini Rev Med Chem"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejps.2015.02.017","volume":"72","author":"Sridevi J.P.","year":"2015","unstructured":"Sridevi J.P.; Suryadevara P.; Janupally R.; Sridhar J.; Soni V.; Anantaraju H.S.; Yogeeswari P.; Sriram D.; Identification of potential Mycobacterium tuberculosis topoisomerase I inhibitors: A study against active, dormant and resistant tuberculosis. Eur J Pharm Sci 2015,72(1),81-92","journal-title":"Eur J Pharm Sci"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2174\/1570193X13666160613094646","volume":"13","author":"D. Joshi","year":"2016","unstructured":"D. Joshi; S.; Kumar, D.; R Dixit, S.; S Joshi, A.; M Aminabhavi, T. Drug resistance of antitubercular agents at the genetic level in mycobacterium species: A road map to drug development for counteracting the resistance. Mini Rev Org Chem 2016,13(4),262-280","journal-title":"Mini Rev Org Chem"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrmicro2236","volume":"7","author":"Barry C.E.","year":"2009","unstructured":"Barry C.E.; Boshoff H.I.; Dartois V.; Dick T.; Ehrt S.; Flynn J.; Schnappinger D.; Wilkinson R.J.; Young D.; The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat Rev Microbiol 2009,7(12),845","journal-title":"Nat Rev Microbiol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1128\/IAI.69.7.4195-4201.2001","volume":"69","author":"Flynn J.L.","year":"2001","unstructured":"Flynn J.L.; Chan J.; Tuberculosis: Latency and reactivation. Infect Immun 2001,69(7),4195-4201","journal-title":"Infect Immun"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cyto.2016.08.030","volume":"88","author":"Zambuzi F.A.","year":"2016","unstructured":"Zambuzi F.A.; Cardoso-Silva P.M.; Espindola M.S.; Soares L.S.; Galvao-Lima L.J.; Brauer V.S.; Gomes M.S.; Amaral L.R.; Schaller M.; Bollela V.R.; Frantz F.G.; Identification of promising plasma immune biomarkers to differentiate active pulmonary tuberculosis. Cytokine 2016,88(1),99-107","journal-title":"Cytokine"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1164\/rccm.201201-0094OC","volume":"186","author":"Meintjes G.","year":"2012","unstructured":"Meintjes G.; Skolimowska K.H.; Wilkinson K.A.; Matthews K.; Tadokera R.; Conesa-Botella A.; Seldon R.; Rangaka M.X.; Rebe K.; Pepper D.J.; Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2012,186(4),369-377","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.15698\/mic2017.03.565","volume":"4","author":"Yang C.S.","year":"2017","unstructured":"Yang C.S.; Advancing host-directed therapy for tuberculosis. Microb Cell 2017,4(3),105","journal-title":"Microb Cell"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejmech.2016.05.025","volume":"121","author":"Joshi S.D.","year":"2016","unstructured":"Joshi S.D.; Kumar D.; Dixit S.R.; Tigadi N.; More U.A.; Lherbet C.; Aminabhavi T.M.; Yang K.S.; Synthesis, characterization and antitubercular activities of novel pyrrolyl hydrazones and their Cu-complexes. \u200e. Eur J Med Chem 2016,121(1),21-39","journal-title":"Eur J Med Chem"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00044-016-1517-y","volume":"25","author":"Joshi S.D.","year":"2016","unstructured":"Joshi S.D.; Kumar D.; More U.A.; Yang K.S.; Aminabhavi T.M.; Design and development of pyrrole carbaldehyde: an effective pharmacophore for enoyl-ACP reductase. Med Chem Res 2016,25(4),672-689","journal-title":"Med Chem Res"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1007\/s00044-014-1053-6","volume":"23","author":"Joshi S.D.","year":"2014","unstructured":"Joshi S.D.; Kumar D.; More U.A.; Aminabhavi T.M.; Docking, CoMFA, and CoMSIA analyses of phenoxy triazole derivatives as enoyl-ACP reductase inhibitors for Escherichia coli. Med Chem Res 2014,23(11),4932-4955","journal-title":"Med Chem Res"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157488551201170502190936","volume":"12","author":"Satheeshkumar S.","year":"2017","unstructured":"Satheeshkumar S.; Amer H.A.; Hojjat Ghasemi G.; Gopal N.; Shushil Kumar S.; Preliminary studies on Ligand-based design and evaluation of new mycobacterial ATP synthase inhibitors. Curr Drug Ther 2017,12(1),1-18","journal-title":"Curr Drug Ther"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"25273","DOI":"10.1074\/jbc.M803899200","volume":"283","author":"Koul A.","year":"2008","unstructured":"Koul A.; Vranckx L.; Dendouga N.; Balemans W.; Van den Wyngaert I.; Vergauwen K.; G\u00f6hlmann H.W.; Willebrords R.; Poncelet A.; Guillemont J.; Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008,283(37),25273-25280","journal-title":"J Biol Chem"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.4155\/fmc.15.128","volume":"7","author":"Kumar D.","year":"2015","unstructured":"Kumar D.; Negi B.; Rawat D.S.; The anti-tuberculosis agents under development and the challenges ahead. Future Med Chem 2015,7(15),1981-2003","journal-title":"Future Med Chem"},{"key":"ref=27","author":"Geiter L.","year":"2000","unstructured":"Geiter L.;  Ending neglect: The elimination of tuberculosis in the United States 2000","journal-title":"Ending neglect: The elimination of tuberculosis in the United States"},{"key":"ref=28","first-page":"1-98","year":"2012","unstructured":"World Health Organization (WHO) Global Tuberculosis Report\n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.who.int\/tb\/publications\/global_report\/gtbr12_main.pdf\">http:\/\/www.who.int\/tb\/publications\/global_report\/gtbr12_main.pdf (Accessed June 11, 2017)2012,1-98"},{"key":"ref=29","first-page":"1-25","year":"2013","unstructured":"US Food and Drug Administration - SIRTURO Prescribing Information\n                     https:\/\/www.accessdata.fda.gov\/drugsatfda_ docs\/label\/2012\/204384s000lbl.pdf\n                    (Accessed June 11, 2017)2013,1-25"},{"key":"ref=30","first-page":"1-26","year":"2013","unstructured":"US Food and Drug Administration. NDA 204-384 Deouty Division Director Summary Review\n                     https:\/\/www.accessdata. fda.gov\/drugsatfda_docs\/nda\/2012\/204384Orig1s000SumR.pdf (Accessed June 11, 2017)2013,1-26"},{"key":"ref=31","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0437","volume":"369","author":"Esmail H.","year":"2014","unstructured":"Esmail H.; Barry C.E.; Young D.B.; Wilkinson R.J.; The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci 2014,369(1645)","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=32","first-page":"1-216","year":"2009","unstructured":"Organization, W.H. Global tuberculosis control: Surveillance, planning, financing ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/apps.who.int\/iris\/bitstream\/10665\/42889\/2\/9241562641.pdf\">http:\/\/apps.who.int\/iris\/bitstream\/10665\/42889\/2\/9241562641.pdf (Accessed June 11, 2017)2009,1-216"},{"key":"ref=33","first-page":"724","volume":"69","author":"Shaw J.B.","year":"1954","unstructured":"Shaw J.B.; Wynn-Williams N.; Infectivity of pulmonary tuberculosis in relation to sputum status. Am Rev Tuberc 1954,69(5),724-732","journal-title":"Am Rev Tuberc"},{"key":"ref=34","first-page":"1","volume":"49","year":"2000","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000,49(RR-6),1-51","journal-title":"MMWR Recomm Rep"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/cid\/cir068","volume":"52","author":"Herrera V.","year":"2011","unstructured":"Herrera V.; Perry S.; Parsonnet J.; Banaei N.; Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection. Clin Infect Dis 2011,52(8),1031-1037","journal-title":"Clin Infect Dis"},{"key":"ref=36","author":"Lessem E.","year":"2016","unstructured":"Lessem E.;  The tuberculosis diagnostics pipeline. Pipeline Report\n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/pipelinereport.org\/2016\/tb-diagnostics\">http:\/\/pipelinereport.org\/2016\/tb-diagnostics (Accessed June 15, 2017).2016"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","volume":"161","year":"2000","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000,161(4 Pt 2),S221-S247","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3121\/cmr.2.3.191","volume":"2","author":"Ayub A.","year":"2004","unstructured":"Ayub A.; Yale S.H.; Reed K.D.; Nasser R.M.; Gilbert S.R.; Testing for latent tuberculosis. Clin Med Res 2004,2(3),191-194","journal-title":"Clin Med Res"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.chest.2017.04.161","volume":"151","author":"Schluger N.W.","year":"2017","unstructured":"Schluger N.W.; Improving the Diagnosis of Latent TB Infection: Tools for TB Elimination? Chest 2017,151(6),1207-1208","journal-title":"Chest"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1164\/arrd.1986.134.5.1048","volume":"134","author":"Slutkin G.","year":"1986","unstructured":"Slutkin G.; Perez-Stable E.J.; Hopewell P.C.; Time course and boosting of tuberculin reactions in nursing home residents. Am Rev Respir Dis 1986,134(5),1048-1051","journal-title":"Am Rev Respir Dis"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1001\/jama.286.14.1740","volume":"286","author":"Mazurek G.H.","year":"2001","unstructured":"Mazurek G.H.; LoBue P.A.; Daley C.L.; Bernardo J.; Lardizabal A.A.; Bishai W.R.; Iademarco M.F.; Rothel J.S.; Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001,286(14),1740-1747","journal-title":"JAMA"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/S0140-6736(00)05115-1","volume":"357","author":"Lalvani A.","year":"2001","unstructured":"Lalvani A.; Pathan A.A.; Durkan H.; Wilkinson K.A.; Whelan A.; Deeks J.J.; Reece W.H.; Latif M.; Pasvol G.; Hill A.V.; Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001,357(9273),2017-2021","journal-title":"Lancet"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1473-3099(07)70086-5","volume":"7","author":"Pai M.","year":"2007","unstructured":"Pai M.; Dheda K.; Cunningham J.; Scano F.; O\u2019Brien R.; T-cell assays for the diagnosis of latent tuberculosis infection: Moving the research agenda forward. Lancet Infect Dis 2007,7(6),428-438","journal-title":"Lancet Infect Dis"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.medmal.2016.02.011","volume":"46","author":"Du F.","year":"2016","unstructured":"Du F.; Zhang Z.; Gao T.; Liu Z.; Jia H.; Xing A.; Du B.; Sun Q.; Cao T.; Diagnosis of latent tuberculosis by ELISPOT assay and tuberculin skin test. Medecine et maladies infectieuses 2016,46(3),150-153","journal-title":"Medecine et maladies infectieuses"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1749-6632.2012.06802.x","volume":"1283","author":"Weiner J.","year":"2013","unstructured":"Weiner J.; Maertzdorf J.; Kaufmann S.H.; The dual role of biomarkers for understanding basic principles and devising novel intervention strategies in tuberculosis. Ann N Y Acad Sci 2013,1283,22-29","journal-title":"Ann N Y Acad Sci"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09247","volume":"466","author":"Berry M.P.","year":"2010","unstructured":"Berry M.P.; Graham C.M.; McNab F.W.; Xu Z.; Bloch S.A.; Oni T.; Wilkinson K.A.; Banchereau R.; Skinner J.; Wilkinson R.J.; Quinn C.; Blankenship D.; Dhawan R.; Cush J.J.; Mejias A.; Ramilo O.; Kon O.M.; Pascual V.; Banchereau J.; Chaussabel D.; O\u2019Garra A.; An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010,466(7309),973-977","journal-title":"Nature"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00109-007-0157-6","volume":"85","author":"Jacobsen M.","year":"2007","unstructured":"Jacobsen M.; Repsilber D.; Gutschmidt A.; Neher A.; Feldmann K.; Mollenkopf H.J.; Ziegler A.; Kaufmann S.H.; Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med (Berl) 2007,85(6),613-621","journal-title":"J Mol Med (Berl)"},{"key":"ref=48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108854","volume":"9","author":"Frediani J.K.","year":"2014","unstructured":"Frediani J.K.; Jones D.P.; Tukvadze N.; Uppal K.; Sanikidze E.; Kipiani M.; Tran V.T.; Hebbar G.; Walker D.I.; Kempker R.R.; Kurani S.S.; Colas R.A.; Dalli J.; Tangpricha V.; Serhan C.N.; Blumberg H.M.; Ziegler T.R.; Plasma metabolomics in human pulmonary tuberculosis disease: A pilot study. PLoS One 2014,9(10)","journal-title":"PLoS One"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(06)69342-2","volume":"368","author":"Agranoff D.","year":"2006","unstructured":"Agranoff D.; Fernandez-Reyes D.; Papadopoulos M.C.; Rojas S.A.; Herbster M.; Loosemore A.; Tarelli E.; Sheldon J.; Schwenk A.; Pollok R.; Rayner C.F.; Krishna S.; Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006,368(9540),1012-1021","journal-title":"Lancet"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri2960","volume":"11","author":"Walzl G.","year":"2011","unstructured":"Walzl G.; Ronacher K.; Hanekom W.; Scriba T.J.; Zumla A.; Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011,11(5),343-354","journal-title":"Nat Rev Immunol"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3109\/00365548.2011.632644","volume":"44","author":"Alsleben N.","year":"2012","unstructured":"Alsleben N.; Ruhwald M.; Russmann H.; Marx F.M.; Wahn U.; Magdorf K.; Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: A case-control study. Scand J Infect Dis 2012,44(4),256-262","journal-title":"Scand J Infect Dis"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1097\/QAD.0b013e32832d3b6d","volume":"23","author":"Lawn S.D.","year":"2009","unstructured":"Lawn S.D.; Myer L.; Edwards D.; Bekker L.G.; Wood R.; Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009,23(13),1717-1725","journal-title":"AIDS"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1002\/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4","volume":"30","author":"van Pinxteren L.A.","year":"2000","unstructured":"van Pinxteren L.A.; Cassidy J.P.; Smedegaard B.H.; Agger E.M.; Andersen P.; Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000,30(12),3689-3698","journal-title":"Eur J Immunol"},{"key":"ref=54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009611","volume":"5","author":"Diedrich C.R.","year":"2010","unstructured":"Diedrich C.R.; Mattila J.T.; Klein E.; Janssen C.; Phuah J.; Sturgeon T.J.; Montelaro R.C.; Lin P.L.; Flynn J.L.; Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One 2010,5(3)","journal-title":"PLoS One"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1128\/IAI.67.8.3980-3988.1999","volume":"67","author":"Serbina N.V.","year":"1999","unstructured":"Serbina N.V.; Flynn J.L.; Early emergence of CD8(+) T cells primed for production of type 1 cytokines in the lungs of Mycobacterium tuberculosis-infected mice. Infect Immun 1999,67(8),3980-3988","journal-title":"Infect Immun"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1128\/IAI.37.3.1042-1049.1982","volume":"37","author":"Wayne L.G.","year":"1982","unstructured":"Wayne L.G.; Lin K.Y.; Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 1982,37(3),1042-1049","journal-title":"Infect Immun"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"11554","DOI":"10.1073\/pnas.96.20.11554","volume":"96","author":"Graham J.E.","year":"1999","unstructured":"Graham J.E.; Clark-Curtiss J.E.; Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS). Proc Natl Acad Sci 1999,96(20),11554-11559","journal-title":"Proc Natl Acad Sci"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1128\/JB.181.23.7161-7167.1999","volume":"181","author":"Zu Bentrup K.H.","year":"1999","unstructured":"Zu Bentrup K.H.; Miczak A.; Swenson D.L.; Russell D.G.; Characterization of Activity and Expression of Isocitrate Lyase in Mycobacterium avium and Mycobacterium tuberculosis. \u200e. J Bacteriol 1999,181(23),7161-7167","journal-title":"J Bacteriol"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/j.1365-2958.2006.05297.x","volume":"61","author":"Gould T.A.","year":"2006","unstructured":"Gould T.A.; Van De Langemheen H.; Mu\u00f1oz-El\u00edas E.J.; McKinney J.D.; Sacchettini J.C.; Dual role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in Mycobacterium tuberculosis. \u200e. Mol Microbiol 2006,61(4),940-947","journal-title":"Mol Microbiol"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tube.2003.08.019","volume":"84","author":"Smith C.V.","year":"2004","unstructured":"Smith C.V.; Sharma V.; Sacchettini J.C.; TB drug discovery: Addressing issues of persistence and resistance. Tuberculosis 2004,84(1),45-55","journal-title":"Tuberculosis"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1074\/jbc.M209248200","volume":"278","author":"Smith C.V.","year":"2003","unstructured":"Smith C.V.; Huang C-c.; Miczak A.; Russell D.G.; Sacchettini J.C.; zu Bentrup K.H.; Biochemical and structural studies of malate synthase from mycobacterium tuberculosis. J Biol Chem 2003,278(3),1735-1743","journal-title":"J Biol Chem"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1471-2334-7-84","volume":"7","author":"Murphy D.J.","year":"2007","unstructured":"Murphy D.J.; Brown J.R.; Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. BMC Infect Dis 2007,7,84","journal-title":"BMC Infect Dis"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.95.16.9578","volume":"95","author":"Yuan Y.","year":"1998","unstructured":"Yuan Y.; Crane D.D.; Simpson R.M.; Zhu Y.Q.; Hickey M.J.; Sherman D.R.; Barry C.E.; The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci USA 1998,95(16),9578-9583","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/JB.187.1.202-212.2005","volume":"187","author":"He H.","year":"2005","unstructured":"He H.; Zahrt T.C.; Identification and characterization of a regulatory sequence recognized by Mycobacterium tuberculosis persistence regulator MprA. J Bacteriol 2005,187,202-212","journal-title":"J Bacteriol"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/JB.01064-13","volume":"196","author":"Bretl D.J.","year":"2014","unstructured":"Bretl D.J.; Bigley T.M.; Terhune S.S.; Zahrt T.C.; The MprB extracytoplasmic domain negatively regulates activation of the Mycobacterium tuberculosis MprAB two-component system. J Bacteriol 2014,196(2),391-406","journal-title":"J Bacteriol"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.1128\/JB.00759-13","volume":"195","author":"Weiss L.A.","year":"2013","unstructured":"Weiss L.A.; Stallings C.L.; Essential roles for Mycobacterium tuberculosis Rel beyond the production of (p) ppGpp. J Bacteriol 2013,195(24),5629-5638","journal-title":"J Bacteriol"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1021\/acs.jcim.5b00150","volume":"55","author":"Singh N.","year":"2015","unstructured":"Singh N.; Tiwari S.; Srivastava K.K.; Siddiqi M.I.; Identification of novel inhibitors of mycobacterium tuberculosis pkng using pharmacophore based virtual screening, docking, molecular dynamics simulation, and their biological evaluation. J Chem Inf Model 2015,55(6),1120-1129","journal-title":"J Chem Inf Model"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.bbrc.2014.03.029","volume":"446","author":"Godbole A.A.","year":"2014","unstructured":"Godbole A.A.; Ahmed W.; Bhat R.S.; Bradley E.K.; Ekins S.; Nagaraja V.; Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison. Biochem Biophys Res Commun 2014,446(4),916-920","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.4155\/fmc-2016-0042","volume":"8","author":"Tse-Dinh Y.C.","year":"2016","unstructured":"Tse-Dinh Y.C.; Targeting bacterial topoisomerases: How to counter mechanisms of resistance. Future Med Chem 2016,8(10),1085-1100","journal-title":"Future Med Chem"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4155\/fmc.14.157","volume":"7","author":"Tse-Dinh Y.C.","year":"2015","unstructured":"Tse-Dinh Y.C.; Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics. Future Med Chem 2015,7(4),459-471","journal-title":"Future Med Chem"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/nar\/28.8.1830","volume":"28","author":"Sikder D.","year":"2000","unstructured":"Sikder D.; Nagaraja V.; Determination of the recognition sequence of Mycobacterium smegmatis topoisomerase I on mycobacterial genomic sequences. Nucleic Acids Res 2000,28(8),1830-1837","journal-title":"Nucleic Acids Res"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/1574-6968.12412","volume":"353","author":"Ahmed W.","year":"2014","unstructured":"Ahmed W.; Menon S.; Godbole A.A.; Karthik P.V.; Nagaraja V.; Conditional silencing of topoisomerase I gene of Mycobacterium tuberculosis validates its essentiality for cell survival. FEMS Microbiol Lett 2014,353(2),116-123","journal-title":"FEMS Microbiol Lett"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.tube.2015.05.004","volume":"95","author":"Ravishankar S.","year":"2015","unstructured":"Ravishankar S.; Ambady A.; Awasthy D.; Mudugal N.V.; Menasinakai S.; Jatheendranath S.; Guptha S.; Sharma S.; Balakrishnan G.; Nandishaiah R.; Ramachandran V.; Eyermann C.J.; Reck F.; Rudrapatna S.; Sambandamurthy V.K.; Sharma U.K.; Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target. Tuberculosis (Edinb) 2015,95(5),589-598","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.drudis.2016.11.006","volume":"22","author":"Nagaraja V.","year":"2017","unstructured":"Nagaraja V.; Godbole A.A.; Henderson S.R.; Maxwell A.; DNA topoisomerase I and DNA gyrase as targets for TB therapy. Drug Discov Today 2017,22(3),510-518","journal-title":"Drug Discov Today"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.04516-14","volume":"59","author":"Godbole A.A.","year":"2015","unstructured":"Godbole A.A.; Ahmed W.; Bhat R.S.; Bradley E.K.; Ekins S.; Nagaraja V.; Targeting Mycobacterium tuberculosis topoisomerase I by small-molecule inhibitors. Antimicrob Agents Chemother 2015,59(3),1549-1557","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/oxfordjournals.jbchem.a124931","volume":"118","author":"Hayashi H.","year":"1995","unstructured":"Hayashi H.; Pyridoxal enzymes: Mechanistic diversity and uniformity. J Biochem 1995,118(3),463-473","journal-title":"J Biochem"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1021\/bi00851a046","volume":"7","author":"Soda K.","year":"1968","unstructured":"Soda K.; Misono H.; L-Lysine: Alpha-ketoglutarate aminotransferase. II. Purification, crystallization, and properties. Biochemistry 1968,7(11),4110-4119","journal-title":"Biochemistry"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"19695","DOI":"10.1038\/srep19695","volume":"6","author":"Duan X.","year":"2016","unstructured":"Duan X.; Li Y.; Du Q.; Huang Q.; Guo S.; Xu M.; Lin Y.; Liu Z.; Xie J.; Mycobacterium Lysine epsilon-aminotransferase is a novel alarmone metabolism related persister gene via dysregulating the intracellular amino acid level. Sci Rep 2016,6,19695","journal-title":"Sci Rep"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrmicro1441","volume":"4","author":"Peschel A.","year":"2006","unstructured":"Peschel A.; Sahl H.G.; The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol 2006,4(7),529-536","journal-title":"Nat Rev Microbiol"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.humimm.2011.03.027","volume":"72","author":"Gonzalez-Curiel I.","year":"2011","unstructured":"Gonzalez-Curiel I.; Casta\u00f1eda-Delgado J.; Lopez-Lopez N.; Araujo Z.; Hernandez-Pando R.; Gandara-Jasso B.; Macias-Segura N.; Enciso-Moreno A.; Rivas-Santiago B.; Differential expression of antimicrobial peptides in active and latent tuberculosis and its relationship with diabetes mellitus. Hum Immunol 2011,72(8),656-662","journal-title":"Hum Immunol"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nri.2016.29","volume":"16","author":"Hancock R.E.","year":"2016","unstructured":"Hancock R.E.; Haney E.F.; Gill E.E.; The immunology of host defence peptides: Beyond antimicrobial activity. Nat Rev Immunol 2016,16(5),321-335","journal-title":"Nat Rev Immunol"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1365-2958.2002.02779.x","volume":"43","author":"Betts J.C.","year":"2002","unstructured":"Betts J.C.; Lukey P.T.; Robb L.C.; McAdam R.A.; Duncan K.; Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002,43(3),717-731","journal-title":"Mol Microbiol"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/2049-632X.12144","volume":"70","author":"Ackart D.F.","year":"2014","unstructured":"Ackart D.F.; Hascall-Dove L.; Caceres S.M.; Kirk N.M.; Podell B.K.; Melander C.; Orme I.M.; Leid J.G.; Nick J.A.; Basaraba R.J.; Expression of antimicrobial drug tolerance by attached communities of Mycobacterium tuberculosis. Pathog Dis 2014,70(3),359-369","journal-title":"Pathog Dis"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.bmc.2017.03.053","volume":"25","author":"Reshma R.S.","year":"2017","unstructured":"Reshma R.S.; Jeankumar V.U.; Kapoor N.; Saxena S.; Bobesh K.A.; Vachaspathy A.R.; Kolattukudy P.E.; Sriram D.; Mycobacterium tuberculosis lysine-varepsilon-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors. Bioorg Med Chem 2017,25(10),2761-2771","journal-title":"Bioorg Med Chem"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.tube.2015.04.010","volume":"95","author":"Devi P.B.","year":"2015","unstructured":"Devi P.B.; Sridevi J.P.; Kakan S.S.; Saxena S.; Jeankumar V.U.; Soni V.; Anantaraju H.S.; Yogeeswari P.; Sriram D.; Discovery of novel lysine varepsilon-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis. Tuberculosis (Edinb) 2015,95(6),786-794","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1107\/S1744309106016824","volume":"62","author":"Tripathi S.M.","year":"2006","unstructured":"Tripathi S.M.; Ramachandran R.; Overexpression, purification and crystallization of lysine epsilon-aminotransferase (Rv3290c) from Mycobacterium tuberculosis H37Rv. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006,62(6),572-575","journal-title":"Acta Crystallogr Sect F Struct Biol Cryst Commun"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/77964","volume":"7","author":"Sharma V.","year":"2000","unstructured":"Sharma V.; Sharma S.; Hoener zu Bentrup K.; McKinney J.D.; Russell D.G.; Jacobs W.R.; Sacchettini J.C.; Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol 2000,7(8),663-668","journal-title":"Nat Struct Biol"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nm1252","volume":"11","author":"Munoz-Elias E.J.","year":"2005","unstructured":"Munoz-Elias E.J.; McKinney J.D.; Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med 2005,11(6),638-644","journal-title":"Nat Med"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1128\/JB.181.23.7161-7167.1999","volume":"181","author":"Honer Zu Bentrup K.","year":"1999","unstructured":"Honer Zu Bentrup K.; Miczak A.; Swenson D.L.; Russell D.G.; Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J Bacteriol 1999,181(23),7161-7167","journal-title":"J Bacteriol"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.tube.2015.12.003","volume":"97","author":"Liu Y.","year":"2016","unstructured":"Liu Y.; Zhou S.; Deng Q.; Li X.; Meng J.; Guan Y.; Li C.; Xiao C.; Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis. Tuberculosis (Edinb) 2016,97,38-46","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1099\/mic.0.26218-0","volume":"150","author":"Saini D.K.","year":"2004","unstructured":"Saini D.K.; Malhotra V.; Dey D.; Pant N.; Das T.K.; Tyagi J.S.; DevR\u2013DevS is a bona fide two-component system of Mycobacterium tuberculosis that is hypoxia-responsive in the absence of the DNA-binding domain of DevR. Microbiology 2004,150(4),865-875","journal-title":"Microbiology"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"12989","DOI":"10.1073\/pnas.2134250100","volume":"100","author":"Sassetti C.M.","year":"2003","unstructured":"Sassetti C.M.; Rubin E.J.; Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci USA 2003,100(22),12989-12994","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1073\/pnas.0306023101","volume":"101","author":"Talaat A.M.","year":"2004","unstructured":"Talaat A.M.; Lyons R.; Howard S.T.; Johnston S.A.; The temporal expression profile of Mycobacterium tuberculosis infection in mice. Proc Natl Acad Sci USA 2004,101(13),4602-4607","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.tube.2004.02.003","volume":"84","author":"Voskuil M.I.","year":"2004","unstructured":"Voskuil M.I.; Visconti K.C.; Schoolnik G.K.; Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis (Edinb) 2004,84(3-4),218-227","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tube.2003.12.010","volume":"84","author":"Hampshire T.","year":"2004","unstructured":"Hampshire T.; Soneji S.; Bacon J.; James B.W.; Hinds J.; Laing K.; Stabler R.A.; Marsh P.D.; Butcher P.D.; Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: A model for persistent organisms? Tuberculosis (Edinb) 2004,84(3-4),228-238","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.1073\/pnas.0503272102","volume":"102","author":"Rengarajan J.","year":"2005","unstructured":"Rengarajan J.; Bloom B.R.; Rubin E.J.; Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci USA 2005,102(23),8327-8332","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-3083.1998.00420.x","volume":"48","author":"Wilkinson R.J.","year":"1998","unstructured":"Wilkinson R.J.; Wilkinson K.A.; De Smet K.A.; Haslov K.; Pasvol G.; Singh M.; Svarcova I.; Ivanyi J.; Human T- and B-cell reactivity to the 16kDa alpha-crystallin protein of Mycobacterium tuberculosis. Scand J Immunol 1998,48(4),403-409","journal-title":"Scand J Immunol"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1365-2249.2003.02201.x","volume":"133","author":"Caccamo N.","year":"2003","unstructured":"Caccamo N.; Barera A.; Di Sano C.; Meraviglia S.; Ivanyi J.; Hudecz F.; Bosze S.; Dieli F.; Salerno A.; Cytokine profile, HLA restriction and TCR sequence analysis of human CD4+ T clones specific for an immunodominant epitope of Mycobacterium tuberculosis 16-kDa protein. Clin Exp Immunol 2003,133(2),260-266","journal-title":"Clin Exp Immunol"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1128\/IAI.01990-06","volume":"75","author":"Geluk A.","year":"2007","unstructured":"Geluk A.; Lin M.Y.; van Meijgaarden K.E.; Leyten E.M.; Franken K.L.; Ottenhoff T.H.; Klein M.R.; T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination. Infect Immun 2007,75(6),2914-2921","journal-title":"Infect Immun"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1086\/344174","volume":"186","author":"Caccamo N.","year":"2002","unstructured":"Caccamo N.; Milano S.; Di Sano C.; Cigna D.; Ivanyi J.; Krensky A.M.; Dieli F.; Salerno A.; Identification of epitopes of Mycobacterium tuberculosis 16-kDa protein recognized by human leukocyte antigen-A*0201 CD8(+) T lymphocytes. J Infect Dis 2002,186(7),991-998","journal-title":"J Infect Dis"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.micinf.2006.03.018","volume":"8","author":"Leyten E.M.","year":"2006","unstructured":"Leyten E.M.; Lin M.Y.; Franken K.L.; Friggen A.H.; Prins C.; van Meijgaarden K.E.; Voskuil M.I.; Weldingh K.; Andersen P.; Schoolnik G.K.; Arend S.M.; Ottenhoff T.H.; Klein M.R.; Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 2006,8(8),2052-2060","journal-title":"Microbes Infect"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1128\/CVI.13.2.179-186.2006","volume":"13","author":"Demissie A.","year":"2006","unstructured":"Demissie A.; Leyten E.M.; Abebe M.; Wassie L.; Aseffa A.; Abate G.; Fletcher H.; Owiafe P.; Hill P.C.; Brookes R.; Rook G.; Zumla A.; Arend S.M.; Klein M.; Ottenhoff T.H.; Andersen P.; Doherty T.M.; Group V.S.; Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 2006,13(2),179-186","journal-title":"Clin Vaccine Immunol"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/bios3030259","volume":"3","author":"Sivaramakrishnan S.","year":"2013","unstructured":"Sivaramakrishnan S.; Ortiz de Montellano P.R.; The DosS-DosT\/DosR Mycobacterial Sensor System. Biosensors 2013,3(3),259-282","journal-title":"Biosensors"},{"key":"ref=104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155522","volume":"11","author":"Giffin M.M.","year":"2016","unstructured":"Giffin M.M.; Shi L.; Gennaro M.L.; Sohaskey C.D.; Role of alanine dehydrogenase of Mycobacterium tuberculosis during recovery from hypoxic nonreplicating persistence. PLoS One 2016,11(5)","journal-title":"PLoS One"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1021\/acs.jmedchem.6b00674","volume":"59","author":"Brunner K.","year":"2016","unstructured":"Brunner K.; Maric S.; Reshma R.S.; Almqvist H.; Seashore-Ludlow B.; Gustavsson A-L.; Poyraz O.m.; Yogeeswari P.; Lundb\u00e4k T.; Vallin M.; Inhibitors of the cysteine synthase CysM with antibacterial potency against dormant Mycobacterium tuberculosis. J Med Chem 2016,59(14),6848-6859","journal-title":"J Med Chem"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"27421","DOI":"10.1074\/jbc.M116.750877","volume":"291","author":"Huang H-L.","year":"2016","unstructured":"Huang H-L.; Krieger I.V.; Parai M.K.; Gawandi V.B.; Sacchettini J.C.; Mycobacterium tuberculosis malate synthase structures with fragments reveal a portal for substrate\/product exchange. J Biol Chem 2016,291(53),27421-27432","journal-title":"J Biol Chem"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/14728222.2017.1327577","volume":"21","author":"Sellamuthu S.","year":"2017","unstructured":"Sellamuthu S.; Singh M.; Kumar A.; Singh S.K.; Type-II NADH Dehydrogenase (NDH-2): A promising therapeutic target for antitubercular and antibacterial drug discovery. Expert Opin Ther Targets 2017,21(6),559-570","journal-title":"Expert Opin Ther Targets"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s13238-011-1100-8","volume":"2","author":"Salaemae W.","year":"2011","unstructured":"Salaemae W.; Azhar A.; Booker G.W.; Polyak S.W.; Biotin biosynthesis in Mycobacterium tuberculosis: Physiology, Biochemistry and Molecular intervention. Protein Cell 2011,2(9),691-695","journal-title":"Protein Cell"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"17531","DOI":"10.1074\/jbc.M801854200","volume":"283","author":"Bashiri G.","year":"2008","unstructured":"Bashiri G.; Squire C.J.; Moreland N.J.; Baker E.N.; Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding. J Biol Chem 2008,283(25),17531-17541","journal-title":"J Biol Chem"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1126\/science.284.5419.1520","volume":"284","author":"Behr M.A.","year":"1999","unstructured":"Behr M.A.; Wilson M.A.; Gill W.P.; Salamon H.; Schoolnik G.K.; Rane S.; Small P.M.; Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999,284(5419),1520-1523","journal-title":"Science"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","volume":"346","author":"Fine P.E.","year":"1995","unstructured":"Fine P.E.; Variation in protection by BCG: Implications of and for heterologous immunity. Lancet 1995,346(8986),1339-1345","journal-title":"Lancet"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/0140-6736(92)90794-4","volume":"339","author":"Ponnighaus J.M.","year":"1992","unstructured":"Ponnighaus J.M.; Fine P.E.; Sterne J.A.; Wilson R.J.; Msosa E.; Gruer P.J.; Jenkins P.A.; Lucas S.B.; Liomba N.G.; Bliss L.; Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992,339(8794),636-639","journal-title":"Lancet"},{"key":"ref=113","first-page":"553","volume":"94","author":"Palmer C.E.","year":"1966","unstructured":"Palmer C.E.; Long M.W.; Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 1966,94(4),553-568","journal-title":"Am Rev Respir Dis"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrmicro1211","volume":"3","author":"Andersen P.","year":"2005","unstructured":"Andersen P.; Doherty T.M.; The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005,3(8),656-662","journal-title":"Nat Rev Microbiol"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/003655401300077144","volume":"33","author":"Fine P.E.","year":"2001","unstructured":"Fine P.E.; BCG: The challenge continues. Scand J Infect Dis 2001,33(4),243-245","journal-title":"Scand J Infect Dis"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1128\/IAI.68.3.1706-1709.2000","volume":"68","author":"Turner J.","year":"2000","unstructured":"Turner J.; Rhoades E.R.; Keen M.; Belisle J.T.; Frank A.A.; Orme I.M.; Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 2000,68(3),1706-1709","journal-title":"Infect Immun"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1552-6909.1999.tb02173.x","volume":"28","author":"Roe V.A.","year":"1999","unstructured":"Roe V.A.; Antimicrobial agents: Pharmacology and clinical application in obstetric, gynecologic, and perinatal infections. J Obstet Gynecol Neonatal Nurs 1999,28(6),639-648","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"key":"ref=118","first-page":"1565","volume":"156","author":"Veldhuyzen van Zanten S.J.","year":"1997","unstructured":"Veldhuyzen van Zanten S.J.; Sherman P.M.; Hunt R.H.; Helicobacter pylori: New developments and treatments. CMAJ 1997,156(11),1565-1574","journal-title":"CMAJ"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1128\/AAC.38.9.2054","volume":"38","author":"Wayne L.G.","year":"1994","unstructured":"Wayne L.G.; Sramek H.A.; Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994,38(9),2054-2058","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4155\/fmc.11.90","volume":"3","author":"Mukherjee T.","year":"2011","unstructured":"Mukherjee T.; Boshoff H.; Nitroimidazoles for the treatment of TB: past, present and future. Future Med Chem 2011,3(11),1427-1454","journal-title":"Future Med Chem"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.2174\/1381612043383214","volume":"10","author":"Barry C.E.","year":"2004","unstructured":"Barry C.E.; Boshoff H.I.; Dowd C.S.; Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr Pharm Des 2004,10(26),3239-3262","journal-title":"Curr Pharm Des"},{"key":"ref=122","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030466","volume":"3","author":"Matsumoto M.","year":"2006","unstructured":"Matsumoto M.; Hashizume H.; Tomishige T.; Kawasaki M.; Tsubouchi H.; Sasaki H.; Shimokawa Y.; Komatsu M.; OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006,3(11)","journal-title":"PLoS Med"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","volume":"405","author":"Stover C.K.","year":"2000","unstructured":"Stover C.K.; Warrener P.; VanDevanter D.R.; Sherman D.R.; A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000,405(6789),962","journal-title":"Nature"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1128\/AAC.01468-06","volume":"51","author":"Iona E.","year":"2007","unstructured":"Iona E.; Giannoni F.; Pardini M.; Brunori L.; Orefici G.; Fattorini L.; Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007,51(4),1537-1540","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","volume":"405","author":"Stover C.K.","year":"2000","unstructured":"Stover C.K.; Warrener P.; VanDevanter D.R.; Sherman D.R.; Arain T.M.; Langhorne M.H.; Anderson S.W.; Towell J.A.; Yuan Y.; McMurray D.N.; Kreiswirth B.N.; Barry C.E.; Baker W.R.; A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000,405(6789),962-966","journal-title":"Nature"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1586\/17476348.2.4.455","volume":"2","author":"Tomioka H.","year":"2008","unstructured":"Tomioka H.; Tatano Y.; Yasumoto K.; Shimizu T.; Recent advances in antituberculous drug development and novel drug targets. Expert Rev Respir Med 2008,2(4),455-471","journal-title":"Expert Rev Respir Med"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.28.5.716","volume":"28","author":"Hooper D.C.","year":"1985","unstructured":"Hooper D.C.; Wolfson J.S.; The fluoroquinolones: Pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 1985,28(5),716-721","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1473-3099(03)00671-6","volume":"3","author":"Ginsburg A.S.","year":"2003","unstructured":"Ginsburg A.S.; Grosset J.H.; Bishai W.R.; Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003,3(7),432-442","journal-title":"Lancet Infect Dis"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/AAC.42.8.2066","volume":"42","author":"Ji B.","year":"1998","unstructured":"Ji B.; Lounis N.; Maslo C.; Truffot-Pernot C.; Bonnafous P.; Grosset J.; \n                        In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998,42(8),2066-2069","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/AAC.43.12.3001","volume":"43","author":"Tomioka H.","year":"1999","unstructured":"Tomioka H.; Sato K.; Akaki T.; Kajitani H.; Kawahara S.; Sakatani M.; Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999,43(12),3001-3004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1128\/AAC.46.4.1022-1025.2002","volume":"46","author":"Alvirez-Freites E.J.","year":"2002","unstructured":"Alvirez-Freites E.J.; Carter J.L.; Cynamon M.H.; \n                        In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002,46(4),1022-1025","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T14:11:21Z","timestamp":1578751881000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172993\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":131,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2019,12,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557519666190625165512","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}